📰 Code Therapeutics News
Page 10 - Code Therapeutics News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Code Therapeutics. Real-time updates on events, politics, business and more.
November 9, 2022
/PRNewswire/ -- The "Global Radiotheranostics Market by Radioisotope, Application, End-user and Region: Competition Forecast and Opportunities to 2027" report...
November 9, 2022
/PRNewswire/ -- The "Global Radiotheranostics Market by Radioisotope, Application, End-user and Region: Competition Forecast and Opportunities to 2027" report...
October 6, 2022
Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks.
July 8, 2022
Kernal Biologics has technology that enables the delivery of messenger RNA therapies to a wider range of destinations in the body. The Series A financing comes as the startup works to advance its lead immuno-oncology program toward its first clinical test.
June 29, 2022
In less than one year, ReCode Therapeutics has reeled in $200 million in financing. Big pharmaceutical companies are taking notice of the biotech startup’s technology, which enables lipid nanoparticles to go a wide range of organs and tissues, potentially broadening the reach of genetic medicines.
June 7, 2022
Code Biotherapeutics uses synthetic DNA as the foundation for its genetic medicines, which the startup claims offer several key advantages compared to genetic medicines delivered via engineered viruses. The startup plans to use its new capital to develop lead programs in Duchenne muscular dystrophy and type 1 diabetes.
May 28, 2022
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) was the recipient of a significant drop in short interest in May. As of May 15th, there was short interest totalling 24,900 shares, a drop of 46.6% from the April 30th total of 46,600 shares. Currently, 0.3% of the shares of the stock are short sold. Based on […]
May 28, 2022
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) was the recipient of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 24,900 shares, a drop of 46.6% from the April 30th total of 46,600 shares. Currently, 0.3% of the company’s stock are sold short. Based […]
May 20, 2022
BOSTON, May 20, 2022 -- TransCode Therapeutics, Inc. today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person venue for the hybrid event is the... | May 20, 2022